Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue: 2015-2023

Historic Non-Current Deffered Revenue for Cartesian Therapeutics (RNAC) over the last 8 years, with Dec 2023 value amounting to $3.5 million.

  • Cartesian Therapeutics' Non-Current Deffered Revenue was N/A to $3.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $3.5 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2023, which is N/A change from last year.
  • Cartesian Therapeutics' Non-Current Deffered Revenue amounted to $3.5 million in FY2023, which was down 69.01% from $11.4 million recorded in FY2021.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Deffered Revenue ranged from a high of $38.7 million in FY2020 and a low of $3.5 million during FY2023.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $7.5 million (2021), whereas its average is $7.5 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first spiked by 163.94% in 2020, then plummeted by 70.53% in 2021.
  • Yearly analysis of 4 years shows Cartesian Therapeutics' Non-Current Deffered Revenue stood at $14.7 million in 2019, then surged by 163.94% to $38.7 million in 2020, then plummeted by 70.53% to $11.4 million in 2021, then reached $3.5 million in 2023.